[EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2014164467A1
公开(公告)日:2014-10-09
The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
[EN] PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] DÉRIVÉS D'ACIDE PYRIDIN-3-YLE ACÉTIQUE UTILISÉS COMME INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
申请人:VIIV HEALTHCARE UK (NO 5) LTD
公开号:WO2017025915A1
公开(公告)日:2017-02-16
Disclosed are compounds of Formula (I), including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
The present invention provides a compound represented by the formula (I):
or a pharmacologically acceptable salt thereof, wherein Ar
1
represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar
2
represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X
1
represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.
[EN] IMIDAZOPYRIMIDINONES AND USES THEREOF<br/>[FR] IMIDAZOPYRIMIDINONES ET LEURS UTILISATIONS
申请人:AVEXA LTD
公开号:WO2010000031A1
公开(公告)日:2010-01-07
The present invention provides a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. The present invention further provides a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. Pharmaceutical compositions comprising a compound of formula (I) are also provided.